VAX-31 + Influenza Vaccine for Pneumonia

This trial tests a new pneumonia vaccine, VAX-31, alongside the seasonal flu vaccine. The goal is to determine if receiving both vaccines together is safe and enhances the immune response in individuals who have never received a pneumonia vaccine. Those in good health with stable chronic conditions and no prior pneumonia vaccine may qualify. Participants will be randomly assigned to receive either both vaccines simultaneously or separately. Their experiences will help researchers assess the effectiveness of this approach. As a Phase 3 trial, this study represents the final step before FDA approval, providing an opportunity to contribute to a potentially groundbreaking treatment.

The trial does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive therapy or certain corticosteroids, you may not be eligible to participate.

Research has shown that VAX-31 is generally well-tolerated, based on earlier studies. Its safety profile resembles that of Prevnar, an already approved vaccine. In past trials, participants reported no serious side effects over six months. This suggests the treatment is generally safe. However, individual experiences may vary with any treatment.¹²³⁴⁵

Unlike the standard of care for pneumonia, which typically involves antibiotics and supportive care, VAX-31 is a vaccine designed to prevent the condition by boosting the body's immune response. Researchers are excited because VAX-31 is administered alongside a seasonal influenza vaccine, potentially providing dual protection against both pneumonia and the flu. This combination could lead to a broader defense strategy, reducing the incidence and severity of pneumonia, especially during flu season. The novel approach of combining two vaccines in one regimen could simplify preventative care and enhance overall effectiveness, making it a promising option for at-risk populations.

Research shows that VAX-31 is designed to protect against various pneumococcal diseases, aiming to prevent about 95% of serious infections and around 88% of pneumococcal pneumonia. Previous studies indicate that VAX-31 is well tolerated, with side effects similar to existing vaccines like Prevnar. It also triggers strong immune responses, helping the body fight infections. In this trial, one group of participants will receive VAX-31 along with the seasonal flu vaccine (SIV), which is about 40% effective against the flu virus each season. Another group will receive a placebo with SIV, followed by VAX-31 at a later time. Together, these vaccines could offer strong protection against both pneumonia and the flu.¹²⁶⁷⁸